US FDA Pharmaceutical Quality Office Lauds Continuous Manufacturing Approvals
The FDA’s OPQ touts approval of sixth and seventh continuously manufactured drugs and quicker delivery of inspection results in latest annual report.
You may also be interested in...
Novartis and Roche will present alongside up-and-coming biotechs and microcaps.
FDA’s calls for more generic industry participation in its Emerging Technology Program fell on deaf ears at recent meeting, with several complaining about the costs and value of investing in new manufacturing technologies.
As pharmaceutical companies begin taking advantage of continuous manufacturing, they are realizing how it can transform an industry rooted in batch processing. Now they have drafted a survival guide.